Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2023-09-01
2023-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Etomidate, Propofol and Etomidate-propofol Combination in Terms of Effects on Haemodynamic Response to Intubation
NCT02186990
Comparison of Propofol/Alfentanil With Propofol/Ketamine
NCT02000206
Atropine-effect During Propofol/Remifentanil Induction
NCT01871922
Impact of Chronic Treatment by β1-adrenergic Antagonists on Nociceptive-Level (NOL) Index Variation After a Standardized Noxious Stimulus Under General Anesthesia
NCT04060095
Comparison of Different Propofol Formulations
NCT01041872
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
AIM OF THE WORK
* The primary aim of this work is to compare atenolol, propranolol, and ivabradine as a premedication to achieve bloodless field anesthesia primarily controlling heart rate in lumbar spine surgery.
* The secondary aims are to assess field visibility and measure the amount of blood loss in patients, and surgeon satisfaction and also to asses if there are any associated undesirable side effects of atenolol, propranolol, or Ivabradine will appear.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atenolol Group
patients will be premedicated with atenolol (50mg)
Atenolol 50 MG
patients will be premedicated with atenolol (50mg)
propranolol Group
patients will be premedicated with propranolol (10mg)
Propranolol Pill
patients will be premedicated with propranolol (10mg)
Ivabradine Group
patients will be premedicated with Ivabradine (5mg)
Ivabradine
patients will be premedicated with Ivabradine (5mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atenolol 50 MG
patients will be premedicated with atenolol (50mg)
Propranolol Pill
patients will be premedicated with propranolol (10mg)
Ivabradine
patients will be premedicated with Ivabradine (5mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* aged from 18 to 50 years old
* scheduled for elective lumber spine surgeries will be included in this study.
Exclusion Criteria
* Hepatic or renal disease.
* Diabetes Mellitus.
* Pregnancy.
* Coagulation disorders.
* Anemia (Hb \< 10 g/dL).
* Ischemic heart disease
* Drug or alcohol abuse.
* Allergy to any of atenolol, propranolol, and ivabradine.
* History of beta-blockers, calcium channel blockers, Tricyclic antidepressants, anticoagulant or clonidine intake.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menoufia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
rabab Mohammad habeeb
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Menoufia University
Shepien El Kom, Menoufia Government, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9/2023ANET 13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.